Monsanto Co. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co.

MTC 2.480

+0.8%

2:52 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Anthony Wong who wrote (739)	12/9/1998 12:14:00 PM
From: John F Beule	Read Replies (2) of 2539

In the year 2000, MTC will be looking to market this drug to treat acute pain. Celebrex, which will compete against MRK is only intended to focus on reducing GI problems while treating arthritis. SC-69124A An injectable COX-2 inhibitor, this compound is formulated for the management of acute pain in a hospital setting. This particular model will compete with IMNX and CNTO. John

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next